Tremfya vs. Ilumya

Tremfya (guselkumab) injection and Ilumya (tildrakizumab-asmn) injection are interleukin-23 blockers used to treat adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Side effects of Tremfya and Ilumya that are similar include upper respiratory infections, injection site reactions (hives, itching, pain, redness, inflammation, swelling, bruising, hematoma, and bleeding), and diarrhea.

Side effects of Tremfya that are different from Ilumya include headache, joint pain, gastroenteritis (nausea, vomiting, diarrhea, cramps, and fever), tinea infections (athlete's foot, ringworm, jock itch), and herpes simplex infections.

Both Tremfya and Ilumya may interact with "live" vaccines.

Tremfya may also interact with CYP450 substrates.

Common side effects of Tremfya include:

• upper respiratory infections,
• headache,
• injection site reactions,
• joint pain,
• diarrhea,
• gastroenteritis (nausea, vomiting, diarrhea, cramps, and fever),
• tinea infections (athlete's foot, ringworm, jock itch), and
• herpes simplex infections

Common side effects of Ilumya include

• upper respiratory infections,
• injection site reactions (hives, itching, pain, redness, inflammation, swelling, bruising, hematoma, and bleeding), and
• diarrhea

Tremfya (guselkumab) injection, for subcutaneous use is an interleukin-23 blocker indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Ilumya (tildrakizumab-asmn) injection is an interleukin-23 antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Tremfya may interact with "live" vaccines and CYP450 substrates. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Tremfya; it is unknown how it would affect a fetus. Human IgG antibodies are known to cross the placental barrier; therefore, Tremfya may be transmitted from the mother to the developing fetus. It is unknown if Tremfya passes into breast milk. Consult your doctor before breastfeeding.

Ilumya may interact with live vaccines. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Ilumya; it is unknown how it would affect a fetus. It is unknown if Ilumya passes into breast milk. Consult your doctor before breastfeeding.

The dose of Tremfya is 100 mg administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter.

The recommended dose of Ilumya is 100 mg at Weeks 0, 4, and every twelve weeks thereafter.